Phase 4 Prostate Cancer Trial, Recruiting NCT06908694 Sponsor: Hamilton Health Sciences Corporation Condition: Prostate Cancer
Back to Prostate Cancer

Phase 4 Prostate Cancer Trial, Recruiting

NCT06908694
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with prostate cancer by a doctor
  • People who are currently receiving, or are planned to receive, a hormone therapy called androgen deprivation therapy (ADT), which may be used alone or combined with other prostate cancer medications
  • People with a body mass index (BMI) of 30 or above, OR a BMI of 27 or above alongside at least one of the following conditions: high blood pressure, type 2 diabetes, obstructive sleep apnea, or high cholesterol/abnormal blood fats

Who may not be able to join:

  • People who have type 1 diabetes
  • People who are currently taking a medication from a class called GLP-1 receptor agonists (a type of diabetes or weight management drug — confirm with trial site if unsure whether a current medication falls into this category)
  • People under 18 years of age
  • People with a history of pancreatitis (inflammation of the pancreas)
  • People with a personal or family history of a specific type of thyroid cancer called medullary thyroid cancer
  • People with a condition called Multiple Endocrine Neoplasia type 2 (a rare inherited condition affecting hormone-producing glands)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Darryl Leong, MBBs,MPH,PhD,FRACP,FESC, Population Health Research Institute and McMaster University

Phone: 905-296-5795

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Hamilton Health Sciences Corporation
Registry
ClinicalTrials.gov
Start date
2 July 2025
Est. completion
31 July 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Number of Serious Adverse Events; Number of Adverse Events leading to Drug Discontinuation; Measure of Weight; Measure of Waist Circumference; Measure of Blood Pressure; Concentration of HbA1c; Concentration of Lipids; Concentration of PSA; Concentration of Creatinine; Calculation of estimated glomerular rate; Number of Clinical Outcomes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov